Physician profile
Dara Derringer
NPI 1972161859
$653.44
in general payments reported to CMS, 2019-2025
15 companies · $35.47 in 2025
The $35.47 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.18 · 2022: $166 · 2023: $114 · 2024: $311 · 2025: $35.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $100.46 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $86.10 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Idorsia Pharmaceuticals US INC | $83.54 | 2024 | Quviviq |
| Abbvie INC. | $76.61 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $66.20 | 2024 | |
| Merck Sharp & Dohme LLC | $59.59 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Otsuka America Pharmaceutical, INC. | $35.97 | 2024 | Rexulti |
| Amgen INC. | $27.26 | 2022-2025 | Evenity, Prolia |
| Mylan Specialty L.P. | $27.18 | 2021 | |
| Grifols USA, LLC | $18.70 | 2024 | Prolastin-C Liquid |
| Acadia Pharmaceuticals INC | $18.32 | 2022 | |
| Electromed, INC. | $18.26 | 2022 | |
| Glaxosmithkline, LLC. | $17.20 | 2023 | Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $12.00 | 2022 | |
| Organon LLC | $6.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dara Derringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.